Cargando…

Intestinal Absorption of Lipids Using a Pancreatic Enzyme-Free Nutritional Supplement in Patients with Cystic Fibrosis: A Randomized, Double-Blind, Crossover Pilot Trial

Nutritional supplements for patients with exocrine pancreatic insufficiency (EPI) typically utilize pancreatic enzyme replacement therapy (PERT) which is associated with gastrointestinal side effects. We evaluated serum triglyceride levels in patients with cystic fibrosis following consumption of an...

Descripción completa

Detalles Bibliográficos
Autores principales: Barto, Tara L., Morency, Clarissa F., Schaap, Nicoline, Patel, Ami B., Monticello, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838800/
https://www.ncbi.nlm.nih.gov/pubmed/35277038
http://dx.doi.org/10.3390/nu14030680
_version_ 1784650214207913984
author Barto, Tara L.
Morency, Clarissa F.
Schaap, Nicoline
Patel, Ami B.
Monticello, Daniel J.
author_facet Barto, Tara L.
Morency, Clarissa F.
Schaap, Nicoline
Patel, Ami B.
Monticello, Daniel J.
author_sort Barto, Tara L.
collection PubMed
description Nutritional supplements for patients with exocrine pancreatic insufficiency (EPI) typically utilize pancreatic enzyme replacement therapy (PERT) which is associated with gastrointestinal side effects. We evaluated serum triglyceride levels in patients with cystic fibrosis following consumption of an enzyme-modified oil oral nutritional supplement (EMO-ONS) versus a standard triacylglycerol-based ONS product (TAG-ONS) used concomitantly with PERT and patient tolerability between the two approaches. Ten subjects with CF and EPI taking PERT were enrolled in a single-center, double-blind, cross-over proof of concept trial. Five subjects randomized to Arm 1 were administered a PERT placebo and EMO-ONS and 5 subjects in Arm 2 were administered TAG-ONS+PERT. After 4 to 14 days, subjects received the opposite ONS. Serum triglyceride levels were measured at baseline and hourly for 6 h. Following the above, subjects were randomly assigned to receive 2 daily servings of EMO-ONS+PERT placebo or TAG-ONS+PERT at home for 7-days, self-reporting gastrointestinal symptoms daily. Mean change in peak serum triglyceride levels were similar for both groups (EMO-ONS = 41.9 ± 46.7 mg/dL vs. TAG-ONS+PERT = 46.4 ± 44.1 mg/L; p = 0.85). There was no difference in mean ratio of the serum triglyceride AUC between the two groups (p = 0.58) or self-reported gastrointestinal tolerance. EMO-based products may provide a PERT-free alternative to traditional ONS products in patients with cystic fibrosis.
format Online
Article
Text
id pubmed-8838800
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88388002022-02-13 Intestinal Absorption of Lipids Using a Pancreatic Enzyme-Free Nutritional Supplement in Patients with Cystic Fibrosis: A Randomized, Double-Blind, Crossover Pilot Trial Barto, Tara L. Morency, Clarissa F. Schaap, Nicoline Patel, Ami B. Monticello, Daniel J. Nutrients Article Nutritional supplements for patients with exocrine pancreatic insufficiency (EPI) typically utilize pancreatic enzyme replacement therapy (PERT) which is associated with gastrointestinal side effects. We evaluated serum triglyceride levels in patients with cystic fibrosis following consumption of an enzyme-modified oil oral nutritional supplement (EMO-ONS) versus a standard triacylglycerol-based ONS product (TAG-ONS) used concomitantly with PERT and patient tolerability between the two approaches. Ten subjects with CF and EPI taking PERT were enrolled in a single-center, double-blind, cross-over proof of concept trial. Five subjects randomized to Arm 1 were administered a PERT placebo and EMO-ONS and 5 subjects in Arm 2 were administered TAG-ONS+PERT. After 4 to 14 days, subjects received the opposite ONS. Serum triglyceride levels were measured at baseline and hourly for 6 h. Following the above, subjects were randomly assigned to receive 2 daily servings of EMO-ONS+PERT placebo or TAG-ONS+PERT at home for 7-days, self-reporting gastrointestinal symptoms daily. Mean change in peak serum triglyceride levels were similar for both groups (EMO-ONS = 41.9 ± 46.7 mg/dL vs. TAG-ONS+PERT = 46.4 ± 44.1 mg/L; p = 0.85). There was no difference in mean ratio of the serum triglyceride AUC between the two groups (p = 0.58) or self-reported gastrointestinal tolerance. EMO-based products may provide a PERT-free alternative to traditional ONS products in patients with cystic fibrosis. MDPI 2022-02-05 /pmc/articles/PMC8838800/ /pubmed/35277038 http://dx.doi.org/10.3390/nu14030680 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Barto, Tara L.
Morency, Clarissa F.
Schaap, Nicoline
Patel, Ami B.
Monticello, Daniel J.
Intestinal Absorption of Lipids Using a Pancreatic Enzyme-Free Nutritional Supplement in Patients with Cystic Fibrosis: A Randomized, Double-Blind, Crossover Pilot Trial
title Intestinal Absorption of Lipids Using a Pancreatic Enzyme-Free Nutritional Supplement in Patients with Cystic Fibrosis: A Randomized, Double-Blind, Crossover Pilot Trial
title_full Intestinal Absorption of Lipids Using a Pancreatic Enzyme-Free Nutritional Supplement in Patients with Cystic Fibrosis: A Randomized, Double-Blind, Crossover Pilot Trial
title_fullStr Intestinal Absorption of Lipids Using a Pancreatic Enzyme-Free Nutritional Supplement in Patients with Cystic Fibrosis: A Randomized, Double-Blind, Crossover Pilot Trial
title_full_unstemmed Intestinal Absorption of Lipids Using a Pancreatic Enzyme-Free Nutritional Supplement in Patients with Cystic Fibrosis: A Randomized, Double-Blind, Crossover Pilot Trial
title_short Intestinal Absorption of Lipids Using a Pancreatic Enzyme-Free Nutritional Supplement in Patients with Cystic Fibrosis: A Randomized, Double-Blind, Crossover Pilot Trial
title_sort intestinal absorption of lipids using a pancreatic enzyme-free nutritional supplement in patients with cystic fibrosis: a randomized, double-blind, crossover pilot trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838800/
https://www.ncbi.nlm.nih.gov/pubmed/35277038
http://dx.doi.org/10.3390/nu14030680
work_keys_str_mv AT bartotaral intestinalabsorptionoflipidsusingapancreaticenzymefreenutritionalsupplementinpatientswithcysticfibrosisarandomizeddoubleblindcrossoverpilottrial
AT morencyclarissaf intestinalabsorptionoflipidsusingapancreaticenzymefreenutritionalsupplementinpatientswithcysticfibrosisarandomizeddoubleblindcrossoverpilottrial
AT schaapnicoline intestinalabsorptionoflipidsusingapancreaticenzymefreenutritionalsupplementinpatientswithcysticfibrosisarandomizeddoubleblindcrossoverpilottrial
AT patelamib intestinalabsorptionoflipidsusingapancreaticenzymefreenutritionalsupplementinpatientswithcysticfibrosisarandomizeddoubleblindcrossoverpilottrial
AT monticellodanielj intestinalabsorptionoflipidsusingapancreaticenzymefreenutritionalsupplementinpatientswithcysticfibrosisarandomizeddoubleblindcrossoverpilottrial